1. Home
  2. TBPH vs TEN Comparison

TBPH vs TEN Comparison

Compare TBPH & TEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • TEN
  • Stock Information
  • Founded
  • TBPH 2013
  • TEN 1993
  • Country
  • TBPH United States
  • TEN Greece
  • Employees
  • TBPH N/A
  • TEN N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • TEN
  • Sector
  • TBPH Health Care
  • TEN
  • Exchange
  • TBPH Nasdaq
  • TEN NYSE
  • Market Cap
  • TBPH 536.5M
  • TEN 620.9M
  • IPO Year
  • TBPH N/A
  • TEN N/A
  • Fundamental
  • Price
  • TBPH $10.90
  • TEN $19.43
  • Analyst Decision
  • TBPH Strong Buy
  • TEN Buy
  • Analyst Count
  • TBPH 5
  • TEN 2
  • Target Price
  • TBPH $16.60
  • TEN $30.50
  • AVG Volume (30 Days)
  • TBPH 158.6K
  • TEN 267.1K
  • Earning Date
  • TBPH 08-12-2025
  • TEN 09-10-2025
  • Dividend Yield
  • TBPH N/A
  • TEN 7.76%
  • EPS Growth
  • TBPH N/A
  • TEN N/A
  • EPS
  • TBPH N/A
  • TEN 4.46
  • Revenue
  • TBPH $65,266,000.00
  • TEN $799,523,000.00
  • Revenue This Year
  • TBPH $51.74
  • TEN N/A
  • Revenue Next Year
  • TBPH N/A
  • TEN $8.89
  • P/E Ratio
  • TBPH N/A
  • TEN $4.33
  • Revenue Growth
  • TBPH 6.11
  • TEN N/A
  • 52 Week Low
  • TBPH $7.44
  • TEN $13.40
  • 52 Week High
  • TBPH $11.88
  • TEN $26.90
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 45.21
  • TEN 48.86
  • Support Level
  • TBPH $10.90
  • TEN $19.37
  • Resistance Level
  • TBPH $11.26
  • TEN $20.15
  • Average True Range (ATR)
  • TBPH 0.24
  • TEN 0.51
  • MACD
  • TBPH -0.08
  • TEN -0.06
  • Stochastic Oscillator
  • TBPH 2.00
  • TEN 42.23

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About TEN TSAKOS ENERGY NAVIGATION

Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.

Share on Social Networks: